9 citations
,
September 2010 in “Dermatologic therapy” Combining cetirizine and topical steroids can effectively manage severe lichen planus pilaris.
December 2022 in “Indian Journal of Animal Research” Both fluoxetine and clomipramine effectively treat dog lick dermatitis, but fluoxetine works faster with lower recurrence, while clomipramine has fewer side effects.
January 2025 in “Nanoscale” Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
Lupus nephritis patients face more challenges in family planning, work, symptoms, medication, and quality of life than those without it.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
21 citations
,
March 2022 in “Pharmaceuticals” The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
January 2026 in “American Journal of Translational Research” The metoprolol-spironolactone combination improves heart function in patients with coronary heart disease and heart failure.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
14 citations
,
November 2024 in “Pharmaceuticals” Spanlastic nano-vesicles improve famotidine's effectiveness and absorption.
May 2024 in “Reactions weekly”
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
24 citations
,
July 1983 in “Clinical and Experimental Dermatology” Tigason improved hair growth in a boy with monilethrix without side effects.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The research suggests Dutasteride and Solifenacin may be effective against the bacterium causing listeriosis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
10 citations
,
January 2016 in “Dermatologic Clinics” Some acne medications have side effects; doctors should educate patients and may not need to do frequent lab tests for all.
97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
July 1994 in “Annals of Pharmacotherapy” Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
October 2024 in “International Journal For Multidisciplinary Research” Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.